Episode 293: Managing MPNs and the SENTRY Trial With Prithviraj Bose

World-renowned MPN expert Dr. Prithviraj Bose of MD Anderson Cancer Center joins Chadi to explore the latest advances in myeloproliferative neoplasms (MPNs), including the molecular drivers of polycythemia vera, essential thrombocythemia, and myelofibrosis, and how these discoveries are reshaping patient care. The conversation then turns to the landmark phase 3 SENTRY trial, which evaluated frontline selinexor plus ruxolitinib versus ruxolitinib alone for patients with JAK inhibitor–naïve myelofibrosis—a rare blood cancer characterized by bone marrow scarring, splenomegaly, and debilitating symptoms. Dr. Bose discusses the trial's potentially practice-changing results, the benefits and limitations of the combination regimen, and what the data mean for the future standard of care in myelofibrosis. Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. https://www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. https://www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA